ConductScience.org, home

Paper9242542

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Koene HR and 5 others. Blood, 1997. Cited by 676 papers, by iCite.

Cite this record

ConductScience Library. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Papers, record 9242542. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9242542

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.
PubMed
Journal
Blood
PubMed
Year
1997
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
676
iCite
Relative citation ratio, by iCite
13.8
iCite
Revised in PubMed
2024-12-19
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Koene HRH R
2Kleijer MM
3Algra JJ
4Roos DD
5von dem Borne AEA E
6de Haas MM

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunoglobulin GMajor topic
Killer Cells, NaturalMajor topic
Receptors, IgGMajor topic
Alleles
Antibodies, Monoclonal
Genotype
Humans
Phenotype
Polymorphism, Genetic
Protein Binding

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00590941Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell LymphomaBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by339

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 676 citations.

PMIDTitleJournalYearIn PapersSource
42926294Analytical Assessment of Fc-Receptor Binding of Therapeutic IgG1 Antibodies: A Surface Plasmon Resonance Approach.Methods Mol Biol2027https://conductscience.org/library/papers/42926294PubMed
42889072Identification of a novel, expressed, alternatively spliced FCER1G protein that inhibits receptor function.Front Immunol2026https://conductscience.org/library/papers/42889072PubMed
42571998Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell-Activating Properties in B Cell Lymphoma.J Extracell Vesicles2026https://conductscience.org/library/papers/42571998PubMed
42505378Next-Generation Multi-Engager Complexes Linking Natural Killer Cells to Tumor Cells and Targeting the Proteolytic Checkpoint ADAM17.Cells2026https://conductscience.org/library/papers/42505378PubMed
42410642ADAM17 blockade restores natural killer cell antibody-dependent cytotoxicity against human immunodeficiency virus-1.Virol J2026https://conductscience.org/library/papers/42410642PubMed
41992203FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy.Cancer Cell Int2026https://conductscience.org/library/papers/41992203PubMed
41928770A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis.Ther Adv Neurol Disord2026https://conductscience.org/library/papers/41928770PubMed
41912269HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering.J Immunother Cancer2026https://conductscience.org/library/papers/41912269PubMed
41827873Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies.Cells2026https://conductscience.org/library/papers/41827873PubMed
41694365Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicity.Front Immunol2026https://conductscience.org/library/papers/41694365PubMed
41515926Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications.Int J Mol Sci2025https://conductscience.org/library/papers/41515926PubMed
41219228A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors.Nat Commun2025https://conductscience.org/library/papers/41219228PubMed
41188903Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.J Transl Med2025https://conductscience.org/library/papers/41188903PubMed
40882026Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell-Mediated Immunomodulation.Cancer Res2025https://conductscience.org/library/papers/40882026PubMed
40873276Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment.Curr Neuropharmacol2026https://conductscience.org/library/papers/40873276PubMed
40728959FCGR2A-131R Is Associated with Lupus Nephritis Rather than Non-Lupus Nephritis SLE in an Indigenous African Caribbean Population.Curr Issues Mol Biol2025https://conductscience.org/library/papers/40728959PubMed
40682568Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies.Immunology2025https://conductscience.org/library/papers/40682568PubMed
40402577High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19.JCI Insight2025https://conductscience.org/library/papers/40402577PubMed
40332717Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase.BioDrugs2025https://conductscience.org/library/papers/40332717PubMed
40274283CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity.J Immunother Cancer2025https://conductscience.org/library/papers/40274283PubMed

See all 339 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FCGR3A2214Swiss-Prot's referenceshttps://conductscience.org/library/genes/2214NCBI Gene
IGHG33502PubTator's text mininghttps://conductscience.org/library/genes/3502NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9242542

GET https://conductscience.org/api/papers/v1/9242542/cited_by?page=2